INTRODUCTION
============

Neoadjuvant chemoradiation (nCRT) followed by total mesorectal excision (TME) has been established as a standard therapeutic strategy for locally advanced rectal cancer, based on evidence from randomized controlled trials (RCTs) \[[@b1-ac-2019-03-10]-[@b6-ac-2019-03-10]\]. However, adjuvant chemotherapy (aCT) following TME after nCRT is an extrapolation of this therapeutic strategy for colon cancer \[[@b7-ac-2019-03-10], [@b8-ac-2019-03-10]\]. The national as well as National Comprehensive Cancer Network guidelines recommend aCT after nCRT and TME, irrespective of the final pathological report \[[@b9-ac-2019-03-10]\].

Recent studies have had contradictory results on the benefits of aCT after nCRT and TME, but there has been increasing evidence that good responders displaying node negativity after nCRT do not benefit from aCT \[[@b10-ac-2019-03-10]-[@b17-ac-2019-03-10]\]. Therefore, some investigators have suggested that aCT should not be routinely applied after nCRT in good responders \[[@b10-ac-2019-03-10]-[@b12-ac-2019-03-10]\]. However, even if node negativity is confirmed after nCRT and TME, when standard treatment strategies for high-risk stage 2 colon cancer patients are considered, concerns may arise that omitting aCT will lead to unfavorable oncologic outcomes in patients with advanced T stages (ypT3/4).

Importantly, studies suggesting a lack of benefit from aCT after nCRT in good responders only included patients who had completed their scheduled aCT, or did not clarify whether the patients had completed their scheduled aCT \[[@b10-ac-2019-03-10]-[@b13-ac-2019-03-10]\]. Therefore, these patients were not representative of real-world patients, considering the poor compliance with aCT after nCRT and TME in rectal cancer patients; thus, these studies may have underestimated the effects of aCT. Since previous studies have demonstrated that aCT incompletion worsens the prognosis of colon cancer patients, there may be important clinical implications to investigating the oncologic impact of aCT incompletion after nCRT and TME, along with aCT initiation.

Therefore, this study investigated the benefits of aCT initiation and the oncologic impact of aCT completion after nCRT and TME in ypstage 2 (ypT3/4N0M0) rectal cancer patients.

METHODS
=======

From a prospectively collected database, we identified patients who had undergone curative resection after nCRT from January 2006 to December 2012 and who exhibited ypN0 on their final pathological reports. Patients who had histories of malignancies in other organs within 5 years, had been diagnosed with hereditary colorectal cancer or recurrent rectal cancer, had undergone palliative surgery or had been treated postoperatively with additional radiotherapy (RT) were excluded. Patients who underwent surgery or switched treatment regimens for palliative purposes due to early local recurrence (LR) or distant metastasis (DM) during the 4 months of planned aCT were also excluded from the final analysis. This study was approved by the Institutional Review Board of Severance Hospital (4-2018-1130) for exemption of informed consent.

In total, 152 patients were included, of whom 139 received aCT and 13 did not. We retrospectively reviewed the patients' electronic medical data to obtain each patient's age, sex, body mass index, American Society of Anesthesiologists physical status classification, preoperative carcinoembryonic antigen (CEA) level, tumor level, clinical stage, nCRT regimen, name and type (minimally invasive \[laparoscopic or robotic\] vs. open) of surgery, anastomotic leakage, hospital stay, histology, tumor regression grade (Mandard grade), pathological stage, tumor size, number of retrieved nodes, circumferential resection margin (CRM), lymphovascular invasion, radicality of resection, initiation and completion of aCT, and aCT regimen. Variables were compared among patients who did not receive aCT (no-aCT), patients who initiated but did not complete aCT (aCT-incompletion) and patients who completed aCT (aCT-completion). We analyzed factors affecting disease-free survival (DFS) and overall survival (OS). Completion of aCT was defined as the completion of scheduled aCT, and incompletion was defined as discontinuation within 4 months of aCT initiation for any reason.

For pretreatment workups, a digital rectal exam, colonoscopy, abdominopelvic computed tomography (CT), pelvic magnetic resonance imaging (MRI) and chest CT were conducted, and the clinical stage was determined based on the results of these pretreatment workups. Patients with clinical T3/4Nany or TanyN+ cancers were treated with nCRT. For the nCRT protocol, the majority of patients received 5-fluorouracil (5-FU)-based longcourse RT (5-FU 400 mg/m^2^/day and leucovorin \[LV\] 20 mg/m^2^/day for 5 days on days 1--5 and days 29--33 or capecitabine 825 mg/m^2^ twice daily for 5 days/wk during long-course RT \[45--50.4 Gy in 25--28 fractions\]). An irinotecan plus S-1 regimen was also used in some patients.

TME was performed within 4--8 weeks of the completion of nCRT. Within 4--6 weeks of surgery, aCT was administered. The regimens for aCT included a bolus injection of FL (5-FU 400 mg/m^2^/day and LV 20 mg/m^2^/day for 5 days every 4 weeks for 4 cycles) or oral capecitabine (1,250 mg/m^2^ twice daily for 2 weeks every 3 weeks for 6 cycles) and a FOLFOX regimen (infusion of oxaliplatin 85 mg/m^2^ and LV 200 mg/m^2^ followed by a bolus of 5-FU 400 mg/m^2^ and continuous infusion of 5-FU 2400 mg/m^2^ for 2 days every 2 weeks for 8 cycles). We defined incompletion of aCT as administration of aCT for less than 4 months.

The patients were followed up every 3 months for 2 years, and then every 6 months for the next 3 years. Physical examinations and chest X-rays were performed and CEA levels were assessed at every visit. Abdominopelvic CT and chest CT were performed at every 6-month and 1-year follow-up, respectively. Colonoscopies were performed 1, 3, and 5 years after surgery. Liver MRI, pelvic MRI or 18-fluorodeoxyglucose-positron emission tomography was performed as needed. DFS was defined as the time to disease progression; OS was defined as the time interval between surgery and death.

Categorical variables were analyzed by the chi-square test or Fisher exact test, and continuous variables were analyzed by Student t-test or the Mann-Whitney U-test. Kaplan-Meier curves were constructed for OS and DFS, and survival outcomes were compared through a log rank test. Prognostic factors for DFS and OS were analyzed with a Cox regression model. P-values \<0.05 were considered statistically significant. IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA) was used for statistical analyses.

RESULTS
=======

In total, 152 patients were included in the analysis. The median follow-up duration was 41 months (interquartile range \[IQR\], 30--56 months). The mean age of the patients was 58.8 ± 11.53 years, and 106 patients were male (69.7%). In total, 116 patients received 5-FU-based nCRT (76.3%).

In 13 patients, aCT was not initiated after nCRT and TME: 6 patients refused aCT, 4 developed postoperative complications such as a rectovaginal fistula, anastomotic leakage or surgical site infection, 1 developed a brain infarction after surgery, 1 developed hepatic encephalopathy after surgery, and 1 developed severe hand-foot syndrome after nCRT. In the remaining 139 patients, aCT was initiated after nCRT and TME. Among them, 132 patients completed their planned aCT schedules, whereas 7 did not. Of these 7, 2 stopped receiving aCT due to severe side effects of the chemotherapeutic agents, 1 refused to complete the planned schedule and 4 discontinued their aCT for reasons that were not recorded.

The patients' demographics are shown in [Table 1](#t1-ac-2019-03-10){ref-type="table"}. There were no significant differences in patient characteristics among the 3 groups. The 5-year DFS and OS rates of patients with ypstage 2 cancer were 72.5% and 85.3%, respectively. The 5-year DFS rate was 74.8% in the aCT-completion group, 42.9% in the aCT-incompletion group and 58.9% in the no-aCT group; the DFS curves differed significantly with a P-value of 0.029 ([Fig. 1A](#f1-ac-2019-03-10){ref-type="fig"}). Regarding the sites of recurrence, the 5-year LR-free survival rates were 91.6%, 57.1%, and 64.3% (P = 0.001), and the 5-year DMfree survival rates were 81.1%, 57.1%, and 59.3% (P = 0.155) in the aCT-completion, aCT-incompletion and no-aCT groups, respectively. The 5-year OS rate was 88.7% in the aCT-completion group, 53.6% in the aCT-incompletion group and 76.9% in the no-aCT group; the OS curves differed significantly with a P-value \< 0.001 ([Fig. 1B](#f1-ac-2019-03-10){ref-type="fig"}).

Univariate analysis of the prognostic factors for DFS revealed that low rectal cancer, abdominoperineal resection (APR), open surgery, a tumor size \> 2 cm at final pathology, retrieval of \<12 lymph nodes, CRM positivity (≤1 mm), R1 resection and aCT incompletion were associated with poor DFS. Multivariate analysis indicated that open surgery (hazard ratio \[HR\], 2.243; 95% confidence interval \[CI\], 1.099--4.578); P = 0.026), a tumor size \>2 cm (HR, 4.168; 95% CI, 1.661--10.461; P = 0.002), retrieval of \<12 lymph nodes (HR, 2.438; 95% CI, 1.215--4.890; P = 0.012), CRM positivity (HR, 3.673; 95% CI, 1.579--8.542; P = 0.003) and aCT incompletion compared to aCT completion (HR, 7.052; 95% CI, 2.323--21.410; P = 0.001) were independent prognostic factors for poor DFS ([Table 2](#t2-ac-2019-03-10){ref-type="table"}).

Univariate analysis of the prognostic factors for OS revealed that old age (≥60 years), low rectal cancer, a clinical stage of T3/4, APR, open surgery, a long hospital stay (\>10 days), a pathologic stage of ypT4, retrieval of \<12 lymph nodes, CRM positivity, R1 resection, no-aCT initiation compared to aCT initiation, and aCT incompletion or no-aCT initiation compared to aCT completion were associated with a poor prognosis. In multivariate analysis, old age (≥60 years) (HR, 3.840; 95% CI, 1.204--12.251; P = 0.025), open surgery (HR, 20.889; 95% CI, 3.684--118.455; P = 0.001), CRM positivity (HR, 3.965; 95% CI, 1.313-11.976; P = 0.015), aCT incompletion compared to aCT completion (HR, 16.879; 95% CI, 4.372--65.158; P \< 0.001) and no-aCT initiation compared to aCT completion (HR, 26.371; 95% CI, 3.703--187.828; P = 0.001) were independent prognostic factors for poor OS ([Table 3](#t3-ac-2019-03-10){ref-type="table"}).

DISCUSSION
==========

This study demonstrated that, compared with aCT completion, aCT incompletion after nCRT and TME was associated with poor DFS and OS, and lack of aCT initiation was also associated with poor OS in ypstage 2 rectal cancer patients. To the best of our knowledge, this is the first study to investigate the association between completion of planned aCT and survival outcomes in rectal cancer patients treated with nCRT and radical surgery.

For locally advanced rectal cancer, nCRT is a standard treatment. Chemotherapeutic agents are used as radiosensitizers during nCRT, and the doses are not sufficient for systemic control. Moreover, the time interval between diagnosis and aCT initiation is approximately 4--5 months when long-course RT is applied. Therefore, a prolonged time interval between nCRT and surgery may result in failure to eradicate micrometastases by allowing subclinical tumor deposits to grow during the time required to achieve local control \[[@b8-ac-2019-03-10]\]. Many guidelines recommend perioperative treatment for 6 months in rectal cancer, so aCT is conventionally used for 4 months after nCRT and TME in pretreated rectal cancer patients. Given that the duration of planned aCT is shorter in rectal cancer than in colon cancer and that aCT initiation is delayed in pretreated rectal cancer patients, it is logical to question the oncologic impact of aCT incompletion, along with that of aCT initiation.

The use of aCT and failure to complete aCT have been associated with poor survival in stage 3 and high-risk stage 2 colon cancer patients in previous studies \[[@b18-ac-2019-03-10]-[@b20-ac-2019-03-10]\]. In contrast, the benefit and proper duration of aCT have not been determined in pretreated rectal cancer patients. Previous RCTs on aCT after neoadjuvant treatment in rectal cancer patients have reported no survival benefits \[[@b14-ac-2019-03-10]-[@b16-ac-2019-03-10]\]. The European Organization for Research and Treatment of Cancer 222921 trial initially indicated that aCT only benefited good responders exhibiting complete pathological remission or ypstage 1 cancer among pretreated rectal cancer patients; however, the 10-year follow-up results revealed no longterm survival benefits for these patients \[[@b2-ac-2019-03-10], [@b14-ac-2019-03-10]\]. The long-term results from an Italian randomized trial (I-CNR-RT) and the Dutch Colorectal Cancer Group (randomized phase III trial (PROCTOR-SCRIPT trial) also demonstrated no benefit of aCT in patients who had undergone nCRT \[[@b15-ac-2019-03-10], [@b16-ac-2019-03-10]\]. However, these studies included good responders with ypN0 cancer, poor responders with ypN+ cancer and patients who did not complete their planned aCT schedules, exhibiting low compliance rates. Thus, the efficacy of aCT (42.9%--73.6%) might have been underestimated \[[@b14-ac-2019-03-10]-[@b16-ac-2019-03-10]\].

Recent retrospective studies have attempted to identify specific subgroups who might benefit from aCT among rectal cancer patients who had undergone nCRT; however, these studies have had conflicting results \[[@b10-ac-2019-03-10]-[@b13-ac-2019-03-10], [@b17-ac-2019-03-10]\]. The subjects were mostly good responders with ypN0 cancer \[[@b10-ac-2019-03-10]-[@b13-ac-2019-03-10]\]. However, the completion status of planned aCT was not clarified in most of these studies \[[@b10-ac-2019-03-10]-[@b12-ac-2019-03-10]\].

Few studies have focused on ypstage 2 patients. In such patients, the omission of aCT might raise concerns about a poor prognosis, because these patients initially had locally advanced disease, and still exhibited an advanced ypT stage at final pathology, despite displaying node negativity. In one retrospective study that attempted to identify subgroups that would benefit from aCT, no difference in DFS was found among ypstage 2 patients, despite benefits from aCT in the whole population (ypTanyNanyM0) \[[@b17-ac-2019-03-10]\].

When the no-aCT group was used as a reference, the aCT-incompletion group did not exhibit any difference in OS (HR, 0.640; 95% CI, 0.086--4.760; P = 0.663); however, the aCT-completion group exhibited better OS (HR, 0.038; 95% CI, 0.005--0.270; P = 0.001). In addition, when compared to the aCT-completion group, the aCT-incompletion group displayed worse DFS and OS, and the no-aCT group exhibited worse OS. Therefore, based on these findings, it is essential to increase compliance with aCT initiation and ensure the completion of all planned cycles by encouraging patients and properly managing aCT-induced toxicity.

This study had some limitations due to its retrospective nature, such as possible selection bias and type 2 error. The sample size included in the analyses was small, with relatively large data censorship. If more cases of aCT-incompletion and no-aCT had been included, the statistical significance of the demographics of the 3 groups may have been different, leading to a different interpretation of the results. Furthermore, the patients were heterogeneous with respect to their nCRT and aCT regimens; thus, our results cannot be completely applied in clinical practice. Therefore, it is imperative to conduct RCTs to collect firm evidence on the proper aCT duration that will improve the oncologic outcomes of pretreated rectal cancer patients.

In conclusion, this study demonstrated that only the aCT-completion group benefited from aCT after nCRT and TME; the noaCT and aCT-incompletion groups had poor prognoses.

In patients with ypstage 2 rectal cancer, aCT after nCRT and TME affected both DFS and OS; however, aCT incompletion did not have any survival benefit, implying that the initiation of aCT alone does not improve oncologic outcomes. Only aCT completion appears to have survival benefits in pretreated rectal cancer patients. Therefore, it is desirable to improve patient compliance with the completion of aCT, in light of its survival benefits in patients with ypstage 2 rectal cancer.
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###### 

Patient demographics

  Characteristic                        Completion   Incompletion   No-aCT      P-value
  ------------------------------------- ------------ -------------- ----------- ---------
  Age ≥60 yr                            63 (47.7)    3 (42.9)       10 (76.9)   0.123
  Male sex                              94 (71.2)    6 (85.7)       6 (46.2)    0.120
  Body mass index (≥25 kg/m^2^)         26 (19.7)    1 (14.3)       3 (23.1)    0.896
  ASA PS classification ≥ III           4 (3.0)      0 (0)          1 (7.7)     0.511
  Preoperative CEA \>5 μg/L (NA in 1)   50 (38.2)    3 (42.9)       2 (15.4)    0.251
  Low rectal cancer (\<AV 6 cm)         55 (41.7)    4 (57.1)       6 (46.2)    0.713
  ≥cT3                                  127 (96.2)   7 (100)        12 (92.3)   0.578
  cN+                                   96 (72.7)    5 (71.4)       9 (69.2)    0.920
  nCRT regimen                                                                  0.116
   5-FU-based                           99 (75.0)    4 (57.1)       13 (100)    
   TS-1 & irinotecan                    31 (23.5)    3 (42.9)       0 (0)       
   Unknown                              2 (1.5)      0 (0)          0 (0)       
  Operation                                                                     0.758
   Sphincter-saving                     112 (84.8)   7 (100)        11 (84.6)   
   APR                                  20 (15.2)    0 (0)          2 (15.4)    
  Minimally invasive surgery            83 (62.9)    2 (28.6)       9 (69.2)    0.167
  Anastomotic leak                      11 (8.3)     1 (14.3)       1 (7.7)     0.646
  Hospital stay (\>POD\#10)             61 (46.2)    5 (71.4)       7 (53.8)    0.411
  Histology (NA in 1)                                                           0.051
   WD                                   17 (13.0)    2 (28.6)       0 (0)       
   MD                                   108 (82.4)   5 (71.4)       10 (76.9)   
   PD or mucinous                       6 (4.6)      0 (0)          3 (23.1)    
  TRG (NA in 2) MG ≥3                   93 (71.5)    6 (85.7)       12 (92.3)   0.257
  ypT4                                  6 (4.5)      1 (14.3)       2 (15.4)    0.124
  Tumor size \>2 cm                     78 (59.1)    5 (71.4)       9 (69.2)    0.697
  Retrieved nodes \<12                  40 (30.3)    4 (57.1)       5 (38.5)    0.274
  CRM ≤1 mm (NA in 16)                  14 (11.9)    1 (20.0)       4 (30.8)    0.108
  LVI (+)                               10 (7.6)     0 (0)          1 (7.7)     \>0.999
  R1 resection                          4 (3.0)      0 (0)          2 (15.4)    0.108
  aCT regimen                                                                   0.381
   5-FU-based                           124 (93.9)   6 (85.7)       NA          
   FOLFOX                               7 (5.3)      1 (14.3)       NA          
   Unknown                              1 (0.8)      0 (0)          NA          

Values are presented as number (%).

ASA PS, American Society of Anesthesiologists physical status; CEA, carcinoembryonic antigen; AV, anal verge; nCRT, neoadjuvant chemoradiotherapy; 5-FU, 5-fluorouracil; APR, abdominoperineal resection; POD, postoperative day; NA, nonapplicable; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; TRG, tumor regression grade; CRM, circumferential resection margin; LVI, lymphovascular invasion; aCT, adjuvant chemotherapy.

###### 

Prognostic factors of disease-free survival

                                  Univariate analysis     Multivariate analysis                           
  ------------------------------- ----------------------- ----------------------- ----------------------- -------
  Low rectal cancer (\<AV 6 cm)   2.052 (1.057--3.983)    0.034                                           
  Operation                                                                                               
   Sphincter-saving               1                                                                       
   APR                            2.259 (1.014--5.029)    0.032                                           
  Open surgery                    2.834 (1.447--5.552)    0.002                   2.243 (1.099--4.578)    0.026
  Tumor size \>2 cm               2.944 (1.289--6.724)    0.010                   4.168 (1.661--10.461)   0.002
  Retrieved nodes \<12            2.714 (1.410--5.225)    0.003                   2.438 (1.215--4.890)    0.012
  CRM ≤1 mm                       2.950 (1.325--6.565)    0.008                   3.673 (1.579--8.542)    0.003
  R1 resection                    3.418 (1.043--11.196)   0.042                                           
  aCT                                                                                                     
   Completion                     1                                               1                       
   Incompletion                   3.605 (1.263--10.293)   0.017                   7.052 (2.323--21.410)   0.001
  No                              1.759 (0.532--5.808)    0.345                   1.730 (0.496--6.033)    0.390

HR, hazard ratio; CI, confidence interval; AV, anal verge; APR, abdominoperineal resection; CRM, circumferential resection margin; aCT, adjuvant chemotherapy.

###### 

Prognostic factors of overall survival

  Variable                        Univariate analysis      Multivariate analysis                             
  ------------------------------- ------------------------ ----------------------- ------------------------- ---------
  Age ≥ 60 yr                     3.047 (1.116--7.964)     0.023                   3.840 (1.204--12.251)     0.023
  Low rectal cancer (\<AV 6 cm)   2.619 (1.003--6.841)     0.049                                             
  ≥cT3                            0.237 (0.069--0.820)     0.023                                             
  Operation                                                                                                  
   Sphincter-saving               1                                                                          
   APR                            4.159 (1.671--10.349)    0.002                                             
  Open surgery                    10.015 (2.275--44.093)   0.002                   20.889 (3.684--118.455)   0.001
  Hospital stay (\>POD\#10)       6.464 (1.476--28.313)    0.013                                             
  ypT4                            3.720 (1.058--13.078)    0.041                                             
  Retrieved nodes \< 12           3.299 (1.318--7.911)     0.010                                             
  CRM ≤ 1 mm                      4.587 (1.698--12.390)    0.003                   3.965 (1.313--11.976)     0.015
  R1 resection                    7.856 (2.219--27.810)    0.001                                             
  No-aCT vs. initiation of aCT    0.233 (0.066--0.821)     0.023                                             
  aCT                                                                                                        
   Completion                     1                                                                          
   Incompletion                   6.669 (2.122--20.957)    0.001                   16.879 (4.372--65.158)    \<0.001
   No                             5.575 (1.522--20.419)    0.009                   26.371 (3.703--187.828)   0.001

HR, hazard ratio; CI, confidence interval; AV, anal verge; APR, abdominoperineal resection; POD, postoperative day; CRM, circumferential resection margin; aCT, adjuvant chemotherapy.
